Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6643409 | 0.77 | NOS2 (0.41) | NOS2SMN1; SMN2ALDH1A1LMNATLR8 | |
| SCHEMBL13135748 | 0.68 | KDM4E (0.40) | SMN1; SMN2L3MBTL1ALDH1A1LMNATDP1 | |
| SCHEMBL23459661 | 0.66 | NOS2 (0.34) | NOS2 | |
| SCHEMBL14957483 | 0.64 | KDM4E (0.33) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL5370813 | 0.63 | LIMK1 (0.38) | SMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL28827176 | 0.61 | SMN1; SMN2 (0.33) | SMN1; SMN2L3MBTL1ALDH1A1LMNATDP1 | |
| SCHEMBL28566639 | 0.61 | CLK4 (0.42) | NOS2SMN1; SMN2ALDH1A1LMNATLR8 | |
| SCHEMBL23459658 | 0.61 | RPS6KA3 (0.38) | L3MBTL1ALDH1A1HTT | |
| SCHEMBL27899640 | 0.60 | SLC9A1 (0.36) | SMN1; SMN2ALDH1A1LMNATDP1 | |
| SCHEMBL4978700 | 0.58 | CLK4 (0.42) | TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007011285-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-10-20 | — | — | US | disclosed |
| EP-1487824-A1 | DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003074515-A1 | DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | TIE1, TEK, KDR | NOS2 373/4885SMN1; SMN2 3839/4885L3MBTL1 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.